Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



PiR Announces Cambridge Breakfast Briefing with Life Science Entrepreneur, Dr Darrin Disley of Horizon Group plc

Cambridge, UK - PIR is delighted to announce that Dr Darrin Disley, parallel life science entrepreneur, angel investor and enterprise champion is to speak at the PiR CEO Breakfast Forum in Cambridge on Tuesday 17 January.

Read the rest of entry »

e-Therapeutics Appoints Dr. Raymond Barlow as Chief Executive

Oxford, UK - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it has appointed Dr. Raymond Barlow as Chief Executive Officer. Dr. Barlow will take up the role on or before 1 May 2017, at which point he will be appointed to the e-Therapeutics Board of Directors.

Read the rest of entry »

Cell and Gene Therapy World: PCI Clinical Services to Share Expertise in Remote QP Certification of ATMPs

Philadelphia, USA – Leading pharmaceutical provider PCI Clinical Services will bring its expertise to the stage at Cell and Gene Therapy World (January 17-20, 2017) with an international case study on the remote Qualified Person (QP) certification of Advanced Therapy Medicinal Products (ATMPs).

Read the rest of entry »

Chronos Therapeutics Partners with Aptuit for Addictive Behaviour Programmes

Oxford, UK - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, today announced that they have partnered with a subsidiary of Aptuit Holdings LLC (Aptuit) for services related to Chronos’ programme targeting the addictive behaviours of binge eating and alcohol use disorders.

Read the rest of entry »

Takeda to Acquire ARIAD Pharmaceuticals, Inc.

Cambridge, USA & Osaka, Japan – Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion.

Read the rest of entry »

Oxford Immunotec to Present at the 35th Annual J.P. Morgan Healthcare Conference

21 December 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017, at 4:00 p.m. PST (7:00 p.m. EST) at the Westin St. Francis on Union Square in San Francisco, CA.

A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 60 days.

Call for Proof of Concept Proposals

19 December 2016: Didcot, UK - In collaboration with the Harwell HealthTec Cluster.  Proposals are invited for collaborative projects between Industry and members of the Harwell HealthTec Cluster, together with Universities where appropriate. The call is for project definition and proof of concept activities in the Life Sciences and Healthcare arenas that would position the project teams to bid for larger funding opportunities within other programmes and thereby to accelerate the pace of innovation in this area. This call is specifically designed to stimulate industrial engagement with the new HealthTec Cluster at Harwell and kick-start innovative cross-sector collaborations e.g. between medicine and Space, lasers, big data etc. We are very open to new ideas on innovative use of technologies, new applications and processes. Particular themes of interest include environmental exposure and human diseases, ageing, and drug discovery. Proposals to work with more than one Cluster organisation are particula ...

Read the rest of entry »

The BioHub Birmingham® Hosts National Life Science Event: BioBrum – 16th February 2017

15 December 2016: Birmingham, UK - The BioHub Birmingham®, Birmingham’s flagship life science incubator, is hosting its first BioBrum Life Science event on 16th February 2017.  Aimed at pre-revenue life science companies the free event will include talks on finance, intellectual property, effective use of professional networks and business development.  There will also be an opportunity for one-to-one advice sessions with IP, finance and business planning specialists.

Read the rest of entry »

Charnwood Molecular Appoints New Head of Medicinal Chemistry

14 December 2016: Loughborough, UK - CRO, Charnwood Molecular Ltd, appoints Dr James Hitchin as its new Head of Medicinal Chemistry to lead its research services laboratories at BioCity, Nottingham. Dr Hitchin brings extensive experience from across multiple therapeutic areas in drug discovery to the Charnwood team.  James has previously held positions at SAFC Pharma, Pfizer Pharmaceuticals and KemFine Oy.  Most recently he was Senior Medicinal Chemist at the Cancer Research UK Manchester Institute, where he worked on various target classes, including kinases and epigenetic targets from hit identification right through to lead optimization and beyond. “I am looking forward to the challenge of leading Charnwood Molecular’s Medicinal Chemistry division”, states James. “We are experiencing significant growth in our chemistry services business, including an increase in demand for the medicinal chemistry research that we undertake at the BioCity laboratories. Charnwood&rsquo ...

Read the rest of entry »

PiR looks forward to another successful year of growth in 2017

13 December 2012: St Ives, UK - 2016 has proven to be a phenomenal year of success and growth for the specialist life science recruitment company PiR. Team work, client engagement and an in-depth understanding of the market have resulted in PiR’s most exciting and rewarding year to date, as it continues to work with an outstanding array of early-stage, investor-backed life science organisations. The boutique company made several new appointments during 2016, including a client services manager for the interims business, a project administrator and a trainee researcher. Significant promotions have also taken place; Sally Hope is now CEO and Nicola Williams continues to provide the critical back office glue in her new role as Business Operations Director. The growth and development of the team has helped to underpin both the executive search practice, specifically for innovative companies in the gene and cell therapy arenas, and the interims practice, where PiR continues to extend its reach to a sought ...

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.